FNA Logo

Paragon 28, Inc. (FNA) Stock Forecast & Price Prediction

Live FNA Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Medical Devices

$13.06

+0.00 (0.00%)

12 Month Price Forecast For FNA

$13.06
Current Price
$1.10B
Market Cap
6 Ratings
Buy 2
Hold 4
Sell 0
Wall St Analyst Ratings

Distance to FNA Price Forecasts

+53.1%
To High Target of $20.00
-0.5%
To Median Target of $13.00
-8.1%
To Low Target of $12.00

FNA Price Momentum

+0.3%
1 Week Change
+27.4%
1 Month Change
-9.7%
1 Year Change
+26.4%
Year-to-Date Change
-11.6%
From 52W High of $14.78
+180.9%
From 52W Low of $4.65

๐Ÿค” Considering Paragon 28 (FNA)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 2:44 PM UTC

FNA Analyst Ratings & Price Targets

Based on our analysis of 10 Wall Street analysts, FNA has a neutral consensus with a median price target of $13.00 (ranging from $12.00 to $20.00). Currently trading at $13.06, the median forecast implies a -0.5% downside. This outlook is supported by 2 Buy, 4 Hold, and 0 Sell ratings.

The most optimistic forecast comes from David Turkaly at JMP Securities, projecting a 53.1% upside. Conversely, the most conservative target is provided by Matt O'Brien at Piper Sandler, suggesting a 8.1% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

FNA Analyst Consensus

2
Buy
4
Hold
0
Sell

FNA Price Target Range

Low
$12.00
Average
$13.00
High
$20.00
Current: $13.06

Latest FNA Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for FNA.

Date Firm Analyst Rating Change Price Target
Jan 30, 2025 Stephens & Co. Mason Carrico Equal-Weight Downgrade $13.00
Jan 29, 2025 William Blair Brandon Vazquez Market Perform Downgrade $0.00
Jan 29, 2025 Needham Mike Matson Hold Downgrade $13.00
Jan 29, 2025 Canaccord Genuity Kyle Rose Hold Downgrade $0.00
Jan 13, 2025 Needham Buy Reiterates $0.00
Nov 13, 2024 Needham Mike Matson Buy Maintains $13.00
Nov 13, 2024 Canaccord Genuity Kyle Rose Buy Maintains $15.00
Aug 9, 2024 Needham Mike Matson Buy Maintains $11.00
Aug 9, 2024 Piper Sandler Matt O'Brien Overweight Reiterates $12.00
May 9, 2024 JMP Securities David Turkaly Market Outperform Maintains $20.00
May 9, 2024 Piper Sandler Matt O'Brien Overweight Reiterates $15.00
May 9, 2024 Needham Mike Matson Buy Maintains $14.00
Apr 5, 2024 Stephens & Co. George Sellers Overweight Reiterates $18.00
Apr 4, 2024 Needham Mike Matson Buy Reiterates $17.00
Mar 28, 2024 Needham Mike Matson Buy Reiterates $17.00
Mar 27, 2024 Piper Sandler Matt O'Brien Overweight Maintains $18.00
Mar 1, 2024 Needham Mike Matson Buy Maintains $17.00
Nov 8, 2023 Needham Mike Matson Buy Maintains $14.00
Sep 29, 2023 William Blair Brandon Vazquez Outperform Initiates $0.00
Aug 3, 2023 Needham Mike Matson Buy Reiterates $24.00

Stocks Similar to Paragon 28, Inc.

The following stocks are similar to Paragon 28 based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Paragon 28, Inc. (FNA) Financial Data

Paragon 28, Inc. has a market capitalization of $1.10B with a P/E ratio of -18.7x. The company generates $245.00M in trailing twelve-month revenue with a -22.9% profit margin.

Revenue growth is +18.1% quarter-over-quarter, while maintaining an operating margin of -13.6% and return on equity of -33.7%.

Valuation Metrics

Market Cap $1.10B
Enterprise Value $1.17B
P/E Ratio -18.7x
PEG Ratio -27.8x
Price/Sales 4.5x

Growth & Margins

Revenue Growth (YoY) +18.1%
Gross Margin +74.1%
Operating Margin -13.6%
Net Margin -22.9%
EPS Growth +18.1%

Financial Health

Cash/Price Ratio +3.6%
Current Ratio 3.5x
Debt/Equity 80.0x
ROE -33.7%
ROA -8.4%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Paragon 28, Inc. logo

Paragon 28, Inc. (FNA) Company Overview

About Paragon 28, Inc.

What They Do

Develops foot and ankle surgical systems.

Business Model

The company generates revenue by developing, distributing, and selling a wide range of surgical systems and technologies focused on foot and ankle procedures. Its product offerings include plating systems, precision guide technology, and various orthobiologics, which are marketed to hospitals and ambulatory surgery centers through a network of sales representatives and distributors.

Additional Information

Founded in 2010 and headquartered in Englewood, Colorado, Paragon 28, Inc. operates both domestically and internationally, targeting a specialized niche in the orthopedic market. The companyโ€™s innovation in surgical systems, including total ankle replacements and advanced fixation methods, positions it well to meet growing demand in orthopedic surgeries.

Company Information

Sector

Healthcare

Industry

Medical Devices

Employees

574

CEO

Mr. Albert DaCosta

Country

United States

IPO Year

2021

Paragon 28, Inc. (FNA) Latest News & Analysis

FNA stock latest news image
Quick Summary

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Paragon 28, Inc. (NYSE:FNA) investors who bought securities before May 5, 2023. More info is available at bgandg.com/FNA.

Why It Matters

Investigations into Paragon 28 may indicate potential legal issues or financial irregularities, which could impact stock performance and investor sentiment.

Source: Accesswire
Market Sentiment: Neutral
FNA stock latest news image
Quick Summary

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Paragon 28, Inc. (NYSE:FNA) investors who bought securities before May 5, 2023. Visit bgandg.com/FNA for more info.

Why It Matters

The investigation into Paragon 28 may indicate potential legal issues or financial misconduct, which could negatively impact the company's stock value and investor confidence.

Source: Accesswire
Market Sentiment: Neutral
FNA stock latest news image
Quick Summary

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors who purchased Paragon 28, Inc. (NYSE:FNA) securities before May 5, 2023.

Why It Matters

The investigation into Paragon 28 may indicate potential legal issues or financial instability, which could affect stock performance and investor sentiment.

Source: Accesswire
Market Sentiment: Neutral
FNA stock latest news image
Quick Summary

Halper Sadeh LLC is investigating Paragon 28, Inc. for potential securities law violations related to its sale to Zimmer Biomet for $13.00 per share, plus a contingent value right of up to $1.00.

Why It Matters

The investigation into Paragon 28's sale highlights potential legal issues that could impact shareholder value and the future performance of the stock, influencing investor sentiment and decisions.

Source: Accesswire
Market Sentiment: Neutral
FNA stock latest news image
Quick Summary

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Paragon 28, Inc. (NYSE:FNA) investors who bought shares before May 5, 2023. More info is available at bgandg.com/FNA.

Why It Matters

The investigation into Paragon 28 may indicate potential legal issues or financial irregularities, which could impact the company's stock performance and investor sentiment.

Source: Accesswire
Market Sentiment: Neutral
FNA stock latest news image
Quick Summary

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Paragon 28, Inc. (NYSE:FNA) who purchased securities before May 5, 2023. More info at bgandg.com/FNA.

Why It Matters

Legal investigations can signal potential liabilities or wrongdoing, impacting Paragon 28's stock price and investor sentiment, which may lead to volatility for those holding shares.

Source: Accesswire
Market Sentiment: Neutral

Frequently Asked Questions About FNA Stock

What is Paragon 28, Inc.'s (FNA) stock forecast for 2025?

Based on our analysis of 10 Wall Street analysts, Paragon 28, Inc. (FNA) has a median price target of $13.00. The highest price target is $20.00 and the lowest is $12.00.

Is FNA stock a good investment in 2025?

According to current analyst ratings, FNA has 2 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.06. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for FNA stock?

Wall Street analysts predict FNA stock could reach $13.00 in the next 12 months. This represents a -0.5% decrease from the current price of $13.06. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Paragon 28, Inc.'s business model?

The company generates revenue by developing, distributing, and selling a wide range of surgical systems and technologies focused on foot and ankle procedures. Its product offerings include plating systems, precision guide technology, and various orthobiologics, which are marketed to hospitals and ambulatory surgery centers through a network of sales representatives and distributors.

What is the highest forecasted price for FNA Paragon 28, Inc.?

The highest price target for FNA is $20.00 from David Turkaly at JMP Securities, which represents a 53.1% increase from the current price of $13.06.

What is the lowest forecasted price for FNA Paragon 28, Inc.?

The lowest price target for FNA is $12.00 from Matt O'Brien at Piper Sandler, which represents a -8.1% decrease from the current price of $13.06.

What is the overall FNA consensus from analysts for Paragon 28, Inc.?

The overall analyst consensus for FNA is neutral. Out of 10 Wall Street analysts, 2 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $13.00.

How accurate are FNA stock price projections?

Stock price projections, including those for Paragon 28, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.